{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'LIST OF FIGURES', 'Figure 1:', 'Study Schema', '38', 'Figure 2:', 'Study Randomization', '50', '23']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '4.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Table 1:', 'Abbreviations and Specialist Terms', 'Abbreviation', 'Explanation', 'ABW', 'absolute body weight', 'AE', 'adverse event', 'AE-QoL', 'Angioedema Quality of Life Questionnaire', 'ALP', 'alkaline phosphatase', 'ALT', 'alanine aminotransferase', 'API', 'active pharmaceutical ingredient', 'AST', 'aspartate aminotransferase', 'BCRP', 'breast cancer resistance protein', 'BCX7353', 'berotralstat', 'BK', 'bradykinin', 'BMI', 'body mass index', 'BMP', 'di-docosahexaenoyl (22:6)-bis(mono)acylglycerol phosphate', 'C1-INH', 'C1 esterase inhibitor', 'C3', 'complement 3', 'C4', 'complement 4', 'CI', 'confidence interval', 'CK-MB', 'creatine kinase MB isoenzyme', 'CLCR', 'creatinine clearance', 'Cmax', 'maximum plasma concentration of the drug', 'COVID-19', 'coronavirus disease 2019', 'CRA', 'clinical research associate', 'CSR', 'clinical study report', 'CYP', 'cytochrome P450', 'DMC', 'Data Monitoring Committee', 'DMID', 'Division of Microbiology and Infectious Diseases, US National Institutes of Allergy and', 'Infectious Diseases', 'EC50', 'concentration that elicits a 50% response', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'e-diary', 'electronic diary', 'EOS', 'end-of-study', 'EOSI', 'event of special interest', 'EQ-5D-5L', 'EuroQoL 5-dimensional, 5-level questionnaire', 'FDA', 'US Food and Drug Administration', 'FSH', 'follicle-stimulating hormone', 'GCP', 'Good Clinical Practice', 'GGT', 'gamma-glutamyltransferase', 'GI', 'gastrointestinal', 'HAE', 'hereditary angioedema', 'HBV', 'hepatitis B virus', '24']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Abbreviation', 'Explanation', 'HCV', 'hepatitis C virus', 'hERG', 'human ether-\u00e0-go-go related gene', 'HIV', 'human immunodeficiency virus', 'HK', 'high-molecular weight kininogen', 'HLA', 'human leukocyte antigen', 'IB', \"investigator's brochure\", 'ICxx', 'xx% inhibitory concentration', 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation of Technical Requirements for Pharmaceuticals for', 'Human Use', 'IEC', 'independent ethics committee', 'IMP', 'investigational medicinal product (study drug)', 'INR', 'international normalized ratio', 'IRB', 'institutional review board', 'ITT', 'intent-to-treat', 'IUD', 'intrauterine device', 'IUS', 'intrauterine system', 'IV', 'intravenous', 'IXRS', 'interactive (web or voice) response system', 'LLN', 'lower limit of normal', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MMRM', 'mixed model for repeated measures', 'NGAL', 'neutrophil gelatinase-associated lipocalin', 'NHI', 'National Health Insurance', 'NHP', 'non-human primates', 'NOAEL', 'no observed adverse effect level', 'PBMC', 'peripheral blood mononuclear cells', 'PD', 'pharmacodynamic', 'P-gp', 'p-glycoprotein efflux pump', 'PK', 'pharmacokinetic', 'PKK', 'prekallikrein', 'PLD', 'phospholipidosis', 'PMDA', 'Japan Pharmaceuticals and Medical Devices Agency', 'PP', 'per protocol', 'PR', 'electrocardiographic interval occurring between the onset of the P wave and the QRS', 'complex, representing time for atrial and ventricular depolarization, respectively', 'QD', 'once daily', 'QoL', 'quality of life', 'QRS', 'electrocardiographic deflection between the beginning of the Q wave and termination of the', 'S wave, representing the time for ventricular depolarization', 'QT', 'electrocardiographic interval between the beginning of the Q wave and termination of the', 'T wave, representing the time for both ventricular depolarization and repolarization to occur', '25']\n\n###\n\n", "completion": "END"}